Methadon Hydrochloride Aurobindo (Methadone Hydrochloride)

Methadone Hydrochloride acts on the opioid system and is indicated for the following clinical situations:

• Opioid dependence maintenance therapy: helps sustain abstinence and reduces illicit opioid use.
• Opioid withdrawal management: alleviates withdrawal symptoms during detoxification.
• Severe chronic pain: provides long‑acting analgesia when other opioids are insufficient.

• Methadone Hydrochloride is a full agonist at the mu‑opioid receptor, producing analgesia and opioid‑replacement effects. It also antagonizes NMDA receptors and inhibits the reuptake of serotonin and norepinephrine, contributing to its efficacy in both pain control and reduction of opioid cravings.

Methadone Hydrochloride may cause a range of adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects

• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness: increased sedation, especially after dose initiation.
• Nausea: upset stomach, sometimes with vomiting.
• Sweating: excessive perspiration, particularly during dose adjustments.
• Dry mouth: reduced salivation causing discomfort.
• Weight gain: increased appetite and fluid retention.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening.
• QT interval prolongation: risk of cardiac arrhythmias.
• Adrenal insufficiency: fatigue, hypotension, and electrolyte disturbances.
• Severe hypotension: sudden drop in blood pressure.
• Allergic reactions: rash, itching, or anaphylaxis.
• Seizures: rare neurologic events, especially with high doses.

Methadone Hydrochloride requires careful clinical oversight due to its potency and pharmacologic profile.

• Assess opioid tolerance: confirm patient has prior opioid exposure before initiating therapy.
• Monitor cardiac function: obtain baseline ECG and repeat if dose is increased or risk factors exist.
• Avoid use in acute intoxication: do not start therapy in patients currently intoxicated with other CNS depressants.
• Use caution in hepatic impairment: liver disease may alter drug metabolism.
• Use caution in renal impairment: adjust dosing if severe kidney dysfunction is present.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methadone Hydrochloride interacts with several drug classes; clinicians should review concomitant medications.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates): additive sedation and respiratory depression.
• MAO inhibitors: risk of serotonin syndrome and hypertensive crisis.
• QT‑prolonging agents (e.g., certain antiarrhythmics, fluoroquinolones): heightened arrhythmia risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise methadone plasma levels.
• Potent CYP2B6 inducers (e.g., rifampin): may reduce efficacy.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower methadone concentrations.
• SSRIs and SNRIs: potential for serotonin syndrome.
• Antihistamines: increased sedation.
• Diuretics: may exacerbate electrolyte imbalances.
• Anticonvulsants: possible alteration of seizure threshold.